The old IVF patient: An evidence based approach. Stratis Kolibianakis MD MSc PhD
|
|
- Prosper Robbins
- 6 years ago
- Views:
Transcription
1 The old IVF patient: An evidence based approach Stratis Kolibianakis MD MSc PhD Unit for Human Reproduction 1 st Dept Ob/Gyn Aristotle University of Thessaloniki
2 No conflict of interest
3 How old is old?
4 How old is old? Great inconsistency in the literature regarding the definition of older mothers Klitzman 2016 >35 y, >38 y, >40 y The definition can vary depending on the decade of publication A 35-year-old woman in the 1980s is described as an older mother Robinson et al 1987 In 2007, women of the same age are considered to be part of the younger cohort McMahon et al 2007
5 No universal definition of the old IVF patient
6 How frequently do we encounter old IVF patients?
7 European data EIM 2016 (2011) Aspirations % Age IVF ICSI Kupka et al 2016
8 SART 2014 Age group < > 42 Cycles %
9 Approximately 1/5 of all IVF cycles are performed in patients > 40 years of age
10 The old IVF patient: An evolving problem Proportion of IVF / ICSI cycles performed in women >40 years of age in Europe ( ) IVF ICSI
11 The old IVF patient: An evolving problem Proportion of egg donation cycles performed in women >40 years of age Europe ( ) ED ED
12 Explanations for the increasing proportion of old IVF patients Low awareness of the rapid decrease in fertility with age in reproductive-aged men and women Bretherick et al 2010 Overestimation of the age that women's fertility decreases, and of the odds of success of IVF treatments Peterson et al 2012 Improvement in pregnancy rates leads to a shift towards more older patients in IVF programs Gleicher et al 2006
13 What is the probability of live birth in the old IVF patient?
14 European data EIM 2016 (2011) Deliveries Age IVF ICSI Kupka et al 2016
15 SART 2014 Live birth Age group < > 42 Cycles 40,805 21,137 20,274 10, Live birth % %CI All transfers performed with embryos fresh or frozen originating from a single oocyte retrieval
16 Outcome of 1114 ICSI and embryo transfer cycles of women > 40 years of age Significant decrease in delivery rates per transfer per year No PGS, no blastocyst culture Ciray et al 2006
17 Klipstein et al ,705 IVF cycles in 1,263 women age > 40 years Live birth p<0.001 Age Cycles Live birth /cycle started Tsafrir et al ,217 IVF/ICSI in 381women > 40 years FSH <20 IU/L Live birth p< Age Cycles Delivery /cycle started
18 Serour et al ,386 IVF/ICSI cycles in 1,645 women > 40 years FSH<20 IU/L AMH >0.6 ng/ml Live birth p<0.001 Age >45 Cycles Live birth /cycle started
19 The probability of live birth in women >40 years of age is small and decreases significantly with each additional year
20 What is the probability of cumulative live birth in the old IVF patient?
21 Cumulative delivery rates after ICSI 116 pts 26 pts 236 cycles 66 cycles FSH<15 IU/L Osmanagaoglu et al 2002
22 Cumulative live birth rates after IVF in 66 women aged AFC >5, basal FSH <15 IU/l, regular cycles If during the first IVF/ICSI cycle 3 oocytes were retrieved, a second cycle was not initiated 125 cycles Cycle 1 Cycle 2 Cycle 3 Patients at risk Live births Cumulative Live birth %CI van Disseldorp et al 2007
23 Cumulative pregnancy rates in 1,217 IVF treatment cycles in 318 women > 40 years All patients, FSH < 20 IU/L Tsafrir et al 2007
24 The cumulative probability of pregnancy in women >40 years of age is small (5.7% after 3 cycles)
25 What is the probability of live birth in IVF patients >45 years?
26 Delivery rates in women > 45 years (288 cycles) Only patients with a reasonable chance of achieving a pregnancy were included 19.8%: cancelled due to elevated FSH or ovarian cyst 30.0%: cancelled due to low or no response (<3 follicles) Age Cycles with OPU COCs 2pn Embryos transferred 2.9 Delivery Up to seven embryos were replaced when available Spandorfer et al 2007
27 The old IVF patient Costs implications
28 Cost per live birth from IVF increases with maternal age and order of attempts Griffiths et a 2010 Incremental cost per live birth by maternal age and treatment cycle
29 The cost for treating old IVF patients need to be considered in counseling these patients
30 How many embryos to transfer in the old IVF patient?
31 How many embryos to transfer in the old IVF patient? Age Embryos transferred Live birth An increase in the number of embryos transferred is associated with an increase in the probability of live birth rate (p < 0.001), even after adjusting for age at cycle start Klipstein et al 2006
32 Number of embryos transferred and probability of multiple pregnancy in the old IVF patient Klipstein et al ,705 IVF cycles in 1,263 women > 40 years Live birth p<0.001 Age Twins Triplets Klipstein et al 2006
33 The more embryos transferred the higher the probability of live birth in patients > 40 years of age, however, twins and triplets are still possible
34 The old IVF patient Can we identify predictive factors for the achievement of live birth?
35 Prognostic factors for live birth in the old IVF patient (>40 years) Serum AMH tertiles ng/ml Low <0.48 Middle High >1.23 Cycles Age COCs Embryos obtained Embryos transferred Viable pregnancy/cycle p<0.05 Lee et al 2011
36 Prognostic factors for live birth in the old IVF patient Cut-off AMH level ng/ml ROC AUC p Cycle cancellation Non-pregnancy Lee et al 2011
37 Prognostic factors for live birth in the old IVF patient Live birth Age (years) Overall Cryopreservation No cryopreservation Significantly higher live birth rates in patients with cryopreservation, after adjusting for age at cycle start and number of embryos transferred (p <0.02) Klipstein et al 2006
38 The availability of embryos for cryopreservation after a fresh transfer is associated with a significantly higher probability of live birth in patients > 40 years of age AMH can be used to predict cycle cancellation and non pregnancy in patients > 40 years of age
39 The old IVF patient A viscous cycle Decrease in oocytes number Increase in aneuploidy rates
40 Declining follicle number with advancing age Faddy et al 1992
41 Decreased euploidy rates with increasing maternal age 46,439 embryo biopsies from 6,365 IVF cycles 24-chromosome single-nucleotide polymorphism Demko et al 2016
42 Miscarriage rates in women > 40 years of age Age Cycles Spontaneous abortion % Overall loss % n/a n/a All > Klipstein et al 2006
43 Can PGS be used to manage the old IVF patient?
44 PGS for aneuploidies Advanced maternal age Live birth rate per woman randomised 38.8 vs vs vs vs vs Twisk et al 2011
45 The effect of preimplantation genetic screening on implantation rate in 150 women over 35 years of age FISH Moayeri, et al 2016
46 PGS by FISH is associated with a significantly lower probability of live birth in patients with advanced maternal age
47 Interventions to increase ovarian response Directly or indirectly increase FSH levels Increase in the sensitivity of the developing follicles to FSH
48 Interventions to increase ovarian response Directly or indirectly increase FSH levels Increased doses of FSH, FSH initiation in the luteal phase, long acting FSH, letrozole, short GnRH agonist protocol, GnRH antagonist protocol or different types of FSH
49 Increase in FSH dose Study Age years Comparison COCs Cedrin-Durnerin 2000 n=96 - Decremental dose IU vs. high FSH fixed dose 450 IU 6.4 vs. 6.3 Klinkert 2005 n= vs IU vs. 300 IU 3 vs. 3 no significant differences Berkkanoglu 2010 n= vs vs IU vs. 450 IU vs. 600 IU 5.2 vs. 6.3 vs. 6.6 Lefebvre 2015 n= vs IU vs 600 IU 5 vs vs. 3 (MIIs)
50 Long acting FSH vs. daily FSH 79 poor responders COCs 40.5 years Long acting FSH 3.0 vs. daily FSH years p=0.26 Kolibianakis et al 2015
51 Long acting FSH vs. daily FSH Kolibianakis et al 2015
52 Initiation of FSH during the luteal phase Study Age years comparison COCs luteal vs follicular Rombauts et al 1998 n= vs Initiation of FSH 150 IU during the luteal phase vs after the onset of menses 5 vs. 5.5 Kansal Kalra et al 2008 n= vs IU subcutaneously twice a day, 9 days after spontaneous LH surge On day 1 of menses, the dose was increased to 300 IU twice a day Patients in the follicular arm began rfsh at the maximum dose (300 IU twice a day) 2.5 vs 3.0
53 Antagonists-letrozole vs micro dose flare up High dose FSH IU
54 AL vs. MF COCs % Study Year SMD (95% CI) Weight 33.5 vs Davar (-1.01, -0.18) vs Mohsen (-0.49, 0.52) Overall (-0.90, 0.29) favours Letrozole
55 GnRH agonists vs. GnRH antagonists Griesinger et al 2006 Xiao et al 2011 Pu et al 2013
56 GnRH agonists vs. GnRH antagonists COCs 36.6 vs vs vs vs vs vs vs vs Kolibianakis et al unpublished
57 Short versus long protocol COCs Age: 39.2 vs Age: 36.9 vs WMD %CI: to +1.02
58 GnRH antagonists versus no pituitary suppression Akman et al patients GnRH antagonists/fsh+hmg vs. FSH+HMG Age: 37.3 Age: 38.2 COCs 3.25 vs p=ns
59 Interventions to increase ovarian response Increase in the sensitivity of the developing follicles to FSH Androgens/androgen-modulating agents (Testosterone, DHEA, aromatase inhibitors, rec LH,rec hcg) By influencing the somatotropic axis (GH, pyridostigmine, oral L-arginine)
60 Interventions to increase ovarian response Increase in the sensitivity of the developing follicles to FSH Androgens/androgen-modulating agents (Testosterone, DHEA, aromatase inhibitors, rec LH,rec hcg) by influencing the somatotropic axis (GH, pyridostigmine, oral L-arginine)
61 Addition of testosterone 37.3 vs vs vs vs WMD: COCs 95%CI: to Bosdou et al ESHRE 2016
62 DHEA DHEA pretreatment COCs % Study Year COCs WMD (95% CI) Weight 36.5 vs Artini (-1.23, 3.05) vs Moawad (1.29, 3.51) vs Yeung (-2.44, 3.44) vs Ktob (0.09, 2.11) Overall 1.54 (0.86, 2.23) WMD: %CI: to WMD: % CI: to Kolibianakis et Kolibianakis al unpublishedet al ESHRE 2016 Favours DHEA 329 patients
63 Aromatase inhibitors COCs 37.9 vs vs WMD: % CI: to Kolibianakis et al unpublished
64 rlh addition COCs 31.7 vs vs <37 y 36.3 vs vs vs WMD %CI: to Lehert et al 2014
65 hcg addition 48 women received 600 IU of rec FSH + 75 IU of rec hcg, 51 women received only 600 IU of rec FSH hcg, age: 35.2 years vs. no hcg, age: 34.9 years MIIs 3.8 vs. 5.6 p=0.19 Berkanoglu 2007
66 Interventions to increase ovarian response Increase in the sensitivity of the developing follicles to FSH using androgens/androgen-modulating agents (Testosterone, DHEA, aromatase inhibitors, rec LH,rec hcg) By influencing the somatotropic axis (GH, pyridostigmine, oral L-arginine)
67 Addition of growth hormone COCs % Study Year WMD (95% CI) Weight Bergh (-5.51, 0.51) vs Dor (-4.95, -1.27) vs Kuzuk (2.34, 4.14) vs Eftechar (0.14, 2.46) Overall (-2.91, 2.75) Bosch et al 2016
68 Addition of Pyridostigmine Kim et al, 70 patients Addition of pyridostigmine versus no addition COCs Pyridostigmine: 5.9 vs. no pyridostigmin: 3.7 Age: 36.7 Age: 38.2 WMD % CI: to Kim et al. 1999
69 Addition of L-arginine Addition of L-arginine versus placebo 34 women, mean age: 40.2 COCs: L-arginine: 4.1 vs. Placebo:1.6 WMD = % CI: to Battaglia et al.,1999
70 Can ovarian response be improved in patients with low ovarian reserve? Various interventions Addition of aspirin
71 Addition of aspirin Lok et al., patients GnRH-agonists/HMG Age: 36.0 Aspirin versus placebo Age: 36.9 COCs 3.0 vs. 4.0 WMD: %CI: -2.0 to +1.6
72 Interventions to increase ovarian response Intervention Control COCs Studies Patients Addition of pyridostigmine no addition Addition of L-arginine no addition Long agonist Short agonist DHEA No DHEA Testosterone pretreatment no testosterone GnRH agonists GnRH antagonists Addition of reclh to FSH no addition
73 There is evidence from RCTs to suggest that certain interventions are associated with a small increase in ovarian response, the clinical significance of which, however, is debatable..
74 Various interventions in the old IVF patient
75 Laser-Assisted Hatching in women of advance age Live birth 39.0 vs vs vs 40.0 Favours AH Martins 2011
76 Laser-Assisted Hatching Age Shi et al 2016
77 Assisted hatching does not increase the probability of live birth in women with advanced maternal age
78 The old IVF patient Oocyte donation
79 Oocyte donation at advanced maternal age Success rates decline in older recipients Age Live birth % SART data: Yeh et al 2014
80 Oocyte donation at advanced maternal age Live birth rate Age Cycles Adjusted OR 95% CI p ref < <0.001 SART data: Yeh et al 2014
81 Does the probability of pregnancy decrease with maternal age after oocyte donation? Live birth rate Age Cycles Adjusted OR 95% CI P ref < <0.06 SART data: Yeh et al 2014
82 The probability of live birth after oocyte donation is high in old IVF recipients but decreases with increasing maternal age
83 Obstetric risks in the old IVF patient
84 Obstetric outcomes in women less or more than 35 years of age (6619 women with singleton pregnancies) Wang et al 2011
85 Obstetric outcomes in women less or more than 40 years of age (16,427 women) Chan et al 2008
86 Pre-eclampsia in 330 women >40 years of age using their own oocytes after IVF or natural conception 41,5 y 32.5y 41,2 y 32.1y Toshimitsu et al 2014
87 Obstetric outcomes in donor oocyte pregnancies 380 women >43 years of age Risk of preeclampsia Adjusted OR 95% CI Incidence No IVF IVF without oocyte donation IVF with oocyte donation Le Ray et al 2012
88 Obstetric outcomes in 71 donor oocyte pregnancies compared with 108 advanced maternal age in in-vitro fertilization pregnancies Krieg et al 2008
89 Obstetric risks are increased in women with advanced maternal age The risk of preeclampsia is increased after oocyte donation compared to natural conception in women with advanced maternal age The risk of caesarean section and abnormal placentation are increased after oocyte donation compared to IVF using autologous oocytes in women with advanced maternal age
90 How old is old? Is there an age limit above which IVF/oocyte donation should not be offered?
91 How old is old? HFEA Australia No specification for an upper age limit for treatment. Clinics make their own determinations about patients Australia bars IVF after the average age of natural menopause, usually interpreted at 52 years of age ASRM No recommendation about upperage limits for women using their own eggs Guidelines: futility as interventions with less than a 1% likelihood of a live birth, very poor prognosis as odds of >1% but <5% 2004 Postmenopausal pregnancy should be discouraged, but physicians should carefully consider the specifics of each case 2013 Providers should implant embryos in women >50 years only after medical evaluation and should discourage women >55 years from doing so
92 Indian woman in her 70s gives birth to healthy baby boy on third attempt of oocyte donation
93 Conclusions No universal definition of the old IVF patient exits Approximately 1/5 of all IVF cycles are performed in patients > 40 years of age The probability of live birth women >40 years of age is small and decreases significantly with each additional year The cumulative probability of pregnancy in women >40 years of age is small (5.7% after 3 cycles)
94 Conclusions The increasing costs for treating old IVF patients need to be considered in counseling these patients The more embryos transferred the higher the probability of live birth in patients > 40 years of age, however, twins and triplets are still possible The availability of embryos for cryopreservation after a fresh transfer Is associated with a significantly higher probability of live birth in patients > 40 years of age
95 Conclusions AMH can be used to predict cycle cancellation and non-pregnancy in patients > 40 years of age PGS by FISH is associated with a significantly lower probability of live birth in patients with advanced maternal age There is evidence from RCTs to suggest that certain interventions are associated with a small increase in ovarian response, the clinical significance of which, however, is debatable
96 Conclusions The probability of live birth after oocyte donation Is high in old IVF recipients but decreases with increasing maternal age Obstetric risks are increased in women with advanced maternal age undergoing IVF
97 Acknowledgements Chairman: Prof. B.C. Tarlatzis Clinical Academics Prof Dr. G. Grimbizis Prof Dr. G. Pados Prof Dr. H. Bili Prof Dr. L. Zepiridis Unit for Human Reproduction 1 st Dept of OB/Gyn, Aristotle University of Thessaloniki PhD fellows J Bosdou MD MSc Z Oikonomou N Tarlatzi Embryologists Prof K. Chatzimeletiou A. Mitsoli Head Nurse D Savvaidou
Poor & Hyper responders: what is the best approach?
Poor & Hyper responders: what is the best approach? A. La Marca ObGyn Dept University of Modena and Reggio Emilia Italy Center for Reproductive Medicine University Hospital of Modena Italy Criteria used
More informationInfluence ovarian stimulation on oocyte and embryo quality. Prof.Dr. Bart CJM Fauser
Influence ovarian stimulation on oocyte and embryo quality Prof.Dr. Bart CJM Fauser How to balance too much vs too little? Lecture Outline Context ovarian stimulation Impact ovarian stimulation on oocyte
More informationDr Guy Gudex. Director Repromed. 17:00-17:30 Recent Advances in Fertility Management
Dr Guy Gudex Director Repromed 17:00-17:30 Recent Advances in Fertility Management Recent Advances in Fertility Management Practice Nurses Programme NZMA GP CME June 2018 Dr Guy Gudex ART in NZ -2014 ACART
More informationHonorary Fellow of the Royal College of Obs. & Gyn. First Indian to receive FIGO s Distinguished Merit Award for Services towards women s health.
Prof.Duru Shah Founder President The PCOS Society (India) President Elect of the Indian Society for Assisted Reproduction (ISAR) Honorary Fellow of the Royal College of Obs. & Gyn. First Indian to receive
More informationNatural Cycle & Mild stimulation IVF/ICSI in women with Poor Ovarian Response (POR)
Natural Cycle & Mild stimulation IVF/ICSI in women with Poor Ovarian Response (POR) Geeta Nargund Head of Reproductive Medicine St George s Hospital London ISMAAR Terminology Human Reprod Nargund et al
More informationA Tale of Three Hormones: hcg, Progesterone and AMH
A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Interpreting Follicular Phase Progesterone Ernesto Bosch IVI Valencia,
More informationINDICATIONS OF IVF/ICSI
PROCESS OF IVF/ICSI INDICATIONS OF IVF/ICSI IVF is most clearly indicated when infertility results from one or more causes having no other effective treatment; Tubal disease. In women with blocked fallopian
More informationProgesterone and clinical outcomes
Synchronization of Slowly Developing Embryos Restores Implantation Success Richard T. Scott, Jr, MD, HCLD Clinical and Scientific Director, Reproductive Medicine Associates of New Jersey Professor and
More informationTreatment of Poor Responders
Treatment of Poor Responders Pathophysiology of Poor Responders Deficiency in systemic IGF 1 levels (Bahceci, 2007) Lower intra ovarian T levels Reduced FSH receptor expression (Cai, 2007) Bahceci, 2007,
More informationL6: DuoStim: the alternative of oocytes/embryos accumulation programs Carlo Alviggi
L6: DuoStim: the alternative of oocytes/embryos accumulation programs Carlo Alviggi Italy What is the aim of IVF? What is the measure of success in IVF? Cumulative live birth rate per started cycle Live
More informationIs it the seed or the soil? Arthur Leader, MD, FRCSC
The Physiological Limits of Ovarian Stimulation Is it the seed or the soil? Arthur Leader, MD, FRCSC Objectives 1. To consider how ovarian stimulation protocols work in IVF 2. To review the key events
More informationDr. Ernesto Bosch Instituto Valenciano de Infertilidad Valencia, Spain. Declared no potential conflict of interest
Dr. Ernesto Bosch Instituto Valenciano de Infertilidad Valencia, Spain Declared no potential conflict of interest Is there a role for LH in elderly patients? Dr. Ernesto Bosch Instituto Valenciano de Infertilidad.
More informationSTIMULATION AND OVULATION TRIGGERING
STIMULATION AND OVULATION TRIGGERING Professor IOANNIS E. MESSINIS MD, PhD (Aberdeen, UK), FRCOG (UK) Department of Obs/Gynae University of Thessaly Larissa, GREECE DISCLOSURE Nothing to disclose Learning
More informationRaoul Orvieto. The Chaim Sheba Medical Center Tel Hashomer, Israel. Declared no potential conflict of interest
Raoul Orvieto The Chaim Sheba Medical Center Tel Hashomer, Israel Declared no potential conflict of interest LH in antagonist cycles; is the story really written? Raoul Orvieto M.D. Israel Overview Role
More information% Oocyte Donation Pregnancyes (days 3)
Ovulation induction in oocyte donors Roma- September 2007 Dr. José Remohí Dr. Carmen Rubio Dr. Amparo Mercader Dr. Pilar Alama Dr. Marco Melo Evolution of oocyte donation cycles 1500 1500 1000 58% 661
More informationEffect of ovarian stimulation on oocyte quality and embryonic aneuploidy: a prospective, randomised controlled trial
FULL PROJECT TITLE: Effect of ovarian stimulation on oocyte quality and embryonic aneuploidy: a prospective, randomised controlled trial (STimulation Resulting in Embryonic Aneuploidy using Menopur (STREAM)
More informationBest practices of ASRM and ESHRE
Best practices of ASRM and ESHRE Late submission Cortina d Ampezzo, Italy 1-3 March 2012 A joint meeting between the American Society for Reproductive Medicine and the European Society of Human Reproduction
More informationAdvanced age, poor responders and the role of LH supplementation. C. Alviggi University Federico II, Naples, Italy
Advanced age, poor responders and the role of LH supplementation C. Alviggi University Federico II, Naples, Italy LH serum level (IU/L) 20.0 15.0 10.0 5.0 0.0 LH levels during spontaneous and stimulated
More informationIndividualized treatment based on ovarian reserve markers
Individualized treatment based on ovarian reserve markers Prof Dr. Nikolaos P. Polyzos M.D. PhD Professor and Medical Co- Director, Vrije Universiteit Brussel, UZ Brussel, Belgium Professor of Reproduc?ve
More informationDipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche. Tecniche di sincronizzazione ovocitaria. La sincronizzazione follicolare
Dipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche Tecniche di sincronizzazione ovocitaria. La sincronizzazione follicolare Carlo Alviggi The rational of Follicular synchronization
More informationPrinciples of Ovarian Stimulation
Principles of Ovarian Stimulation Dr Genia Rozen Gynaecologist and Fertility Specialist Royal Women s Hospital and Melbourne IVF Learning objectives Why ovarian stimulation Recap physiology Ovarian cycle
More informationUnderstanding IVF Processes in Surrogacy
Melvin H. Thornton II MD Medical Director CT Fertility Understanding IVF Processes in Surrogacy The Basics Surrogacy involves multiple parties IVF CLINIC Egg donors screening and matching* Medical process
More informationScientific Highlights: First world conference on luteinizing hormone in ART: Landing in Asia Pacific
This EXCEMED conference followed on from the First world conference on luteinizing hormone (LH) in ART, which took place in Naples in May 2016. Bringing the topic of LH to Asia Pacific provided an opportunity
More informationPatient Price List. t: e: w:
Patient Price List t: 0333 015 9774 e: enquires@ivi.uk w: www.ivi.uk fertility treatments Pre Treatment Medical Consultation 250 Nurse Planning 200 Baseline ultrasound scan of uterus and ovaries included
More informationA new approach to IVF? Soft or mild IVF. Soft or mild IVF
A new approach to IVF? William Ledger University of Sheffield Centre for Reproductive Medicine and Fertility (w.ledger@sheffield.ac.uk) Soft or mild IVF Less patient discomfort Less complex, shorter stimulation
More informationModified natural cycles: the Italian experience
CLINICA VALLE GIULIA, Rome Modified natural cycles: the Italian experience Filippo Maria Ubaldi M.D. M.Sc. Poor ovarian Response ESHRE Campus symposium Bologna 19-20 March 2010 Introduction Ovarian superovulation
More informationNICE fertility guidelines. Hemlata Thackare MPhil MSc MRCOG Deputy Medical Director London Women s Clinic
NICE fertility guidelines Hemlata Thackare MPhil MSc MRCOG Deputy Medical Director London Women s Clinic About the LWC 4 centres around the UK London Cardiff Swansea Darlington The largest sperm bank in
More informationLOW RESPONDERS. Poor Ovarian Response, Por
LOW RESPONDERS Poor Ovarian Response, Por Patients with a low number of retrieved oocytes despite adequate ovarian stimulation during fertility treatment. Diagnosis Female About Low responders In patients
More informationLH activity administration during the
LH activity administration during the luteal-follicular transition Richard Fleming On behalf of the Luveris Pre-treatment group University of Glasgow Scotland Androgens have a Paracrine action in the Early
More informationInfertility treatment
In the name of God Infertility treatment Treatment options The optimal treatment is one that provide an acceptable success rate, has minimal risk and is costeffective. The treatment options are: 1- Ovulation
More informationA prospective randomised study comparing a GnRH-antagonist versus a GnRH-agonist short protocol for ovarian stimulation in patients referred for IVF
FVV IN OBGYN, 2012, 4 (2): 82-87 Original paper A prospective randomised study comparing a GnRH-antagonist versus a GnRH-agonist short protocol for ovarian stimulation in patients referred for IVF S. GORDTS,
More informationAbstract. Introduction. RBMOnline - Vol 19. No Reproductive BioMedicine Online; on web 24 August 2009
RBMOnline - Vol 19. No 4. 2009 599 603 Reproductive BioMedicine Online; www.rbmonline.com/article/3872 on web 24 August 2009 Article Assisted reproduction in women over 40 years of age: how old is too
More informationInfertility Clinical Guideline
Infertility Clinical Guideline Ovarian Stimulation Guideline Purpose: To provide sufficient background regarding various ovarian stimulation protocols for In Vitro Fertilization cycles. Goal: To assist
More informationIntérêt de l hcg et induction de l ovulation. Christophe Blockeel, MD, PhD Centre for Reproductive Medicine, Brussels, Belgium
Intérêt de l hcg et induction de l ovulation Christophe Blockeel, MD, PhD Centre for Reproductive Medicine, Brussels, Belgium Conflict of interest The opinions expressed in this document are the opinions
More informationFertility Preservation for Breast Cancer. Elizabeth S. Ginsburg MD Medical Director, ART Program Brigham & Women s Hospital
Fertility Preservation for Breast Cancer Elizabeth S. Ginsburg MD Medical Director, ART Program Brigham & Women s Hospital Learning Objectives To be able to list and describe processes of ovulation induction
More informationOptimizing the Management of the Poor Responder. Kaylen Silverberg, M.D. Texas Fertility Center Austin, Texas
Optimizing the Management of the Poor Responder Kaylen Silverberg, M.D. Texas Fertility Center Austin, Texas 2 Choices Donor Oocytes Break, eat, visit, enjoy weather Listen to lecture Argue, get grumpy,
More informationThe emergence of Personalized Medicine protocols for IVF.
Individualising IVF: Introduction to the POSEIDON Concept Introduction The emergence of Personalized Medicine protocols for IVF. Differences between patients: age, ovarian reserve, BMI or presence of ovarian
More informationAbstract. Introduction. Materials and methods. Patients and methods
RBMOnline - Vol 8. No 3. 344-348 Reproductive BioMedicine Online; www.rbmonline.com/article/1178 on web 20 January 2004 Article Cumulative live birth rates after transfer of cryopreserved ICSI embryos
More informationSample size a Main finding b Main limitations
1 Table 1. Available studies on the relation between endometriosis and miscarriage (1995-2015). Study (citation) Country Study period Study design Sample size a Main finding b Main limitations Matoras
More informationMilder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization
Milder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization Revelli et al. Reproductive Biology and Endocrinology 2011, 9:25 Presenter: R2 孫怡虹 Background
More informationInfertility in Women over 35. Alison Jacoby, MD Dept. of Ob/Gyn UCSF
Infertility in Women over 35 Alison Jacoby, MD Dept. of Ob/Gyn UCSF Learning Objectives Review the effect of age on fertility Fertility counseling for the patient >35 - timing - lifestyle - workup Fertility
More informationFemale Reproductive Physiology. Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF
Female Reproductive Physiology Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF REFERENCE Lew, R, Natural History of ovarian function including assessment of ovarian reserve
More informationThe Jones Institute for Reproductive Medicine Founded on Science, Dedicated to Life
The Jones Institute for Reproductive Medicine Founded on Science, Dedicated to Life Assisted reproductive technologies: State-of-the-ART Sergio Oehninger, MD, PhD Professor and Vice-Chair, Dept. Ob/Gyn
More informationPredictive factors of successful pregnancy after assisted reproductive technology in women aged 40 years and older
Reprod Med Biol (2009) 8:145 149 DOI 10.1007/s12522-009-0023-z ORIGINAL ARTICLE Predictive factors of successful pregnancy after assisted reproductive technology in women aged 40 years and older Akihisa
More informationPrice List. Valid from 1 st April 2017
Price List Valid from 1 st April 2017 Consultations & Assessments Consultations & Tests Medical Consultation 200 Nurse Planning Consultation (includes ultrasound scan) 230 Consultation with Counsellor
More informationMinimising IVF related mortality and morbidity. Scott Nelson Muirhead Professor in Obstetrics & Gynaecology
Minimising IVF related mortality and morbidity Scott Nelson Muirhead Professor in Obstetrics & Gynaecology We rarely say no - so what I will cover today VTE as an example of a modifiable IVF complication
More informationAre all-freeze cycles & frozen-thawed embryo transfers improving IVF outcomes?
Are all-freeze cycles & frozen-thawed embryo transfers improving IVF outcomes? Andrea Weghofer Foundation for Reproductive Medicine 2017 New York, November 16-19 Conflict of interest No relevant financial
More informationA Tale of Three Hormones: hcg, Progesterone and AMH
A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Human Ovarian Steroidogenesis and Gonadotrophin Stimulation Johan
More informationFertility Policy. December Introduction
Fertility Policy December 2015 Introduction Camden Clinical Commissioning Group (CCG) is responsible for commissioning a range of health services including hospital, mental health and community services
More informationOvarian hyperstimulation syndrome (OHSS)
Ovarian hyperstimulation syndrome (OHSS) OHSS OHSS: exaggerated response to gonadotropins and hcg Characterized by: ovarian enlargement increased vascular permeability fluid accumulation in abdomen Associated
More informationUnderstanding eggs, sperm and embryos. Marta Jansa Perez Wolfson Fertility Centre
Understanding eggs, sperm and embryos Marta Jansa Perez Wolfson Fertility Centre What does embryology involve? Aims of the embryology laboratory Creation of a large number of embryos and supporting their
More informationDo it Once, Do it Right
Do it Once, Do it Right Craig Reisser Andrea Speck-Zulak Families Through Surrogacy 2016 Founded in 1989 - more than 25 years building families patients from 40 countries One of the largest IVF clinics
More informationInternational Federation of Fertility Societies. Global Standards of Infertility Care
International Federation of Fertility Societies Global Standards of Infertility Care Standard 8 Reducing the incidence of multiple pregnancy following treatment for infertility Name Version number Author
More informationEmbryo Selection after IVF
Embryo Selection after IVF Embryo Selection after IVF Many of human embryos produced after in vitro fertilization carry abnormal chromosomes. Placing a chromosomally normal embryo (s) into a normal uterus
More informationHold On To Your Dreams
Hold On To Your Dreams Dr. Michael Kettel Dr. Sandy Chuan 1. THE BASICS OF IVF & EMBRYO DEVELOPMENT 2. IVF ADD-ONS - MYTH VS. SCIENCE IN VITRO FERTILIZATION 1. Ovarian Stimulation 2. Egg Retrieval 3. Create
More informationWhat is the POSEIDON concept?
Improving Success in ART: how to define it and key strategies to get the best outcomes, Kiev, 21-09-2018 What is the POSEIDON concept? Alessandro Conforti Italy Objectives Unravel the definition of POR
More informationI. ART PROCEDURES. A. In Vitro Fertilization (IVF)
DFW Fertility Associates ASSISTED REPRODUCTIVE TECHNOLOGY (ART) Welcome to DFW Fertility Associates/ Presbyterian-Harris Methodist Hospital ARTS program. This document provides an overview of treatment
More information1 (gonadotropin, Gn) -,, : - (IVF-ET); (COH); ; : R711.6 : A : X(2014)
34 10 Vol.34 No.10 2014 10 Oct. 2014 Reproduction & Contraception doi: 10.7669/j.issn.0253-357X.2014.10.0858 E-mail: randc_journal@163.com ( 200001) - : - (IVF-ET); (COH); ; : R711.6 : A : 0253-357X(2014)10-0858-07
More informationIN VITRO FERTILISATION (IVF)
IN VITRO FERTILISATION (IVF) Pre Treatment - first cycle 785 Medical Consultation 225 Nurse Planning 235 Baseline ultrasound scan of uterus and ovaries HIV, Hep B antibodies, Hep B antigen, Hep C blood
More informationLUTEAL PHASE SUPPORT. Doç. Dr. Nafiye Yılmaz. Zekai Tahir Burak Kadın Sağlığı Eğitim Araştırma Hastanesi
LUTEAL PHASE SUPPORT Doç. Dr. Nafiye Yılmaz Zekai Tahir Burak Kadın Sağlığı Eğitim Araştırma Hastanesi TAJEV, 2014 1 ART & success *Live birth rate 2 Optimal luteal phase Etiology of luteal phase deficiency
More informationInterpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used
Interpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used Ellenbogen A., M.D., Shalom-Paz E., M.D, Asalih N., M.D, Samara
More informationHow to make the best use of the natural cycle for frozen-thawed embryo transfer?
How to make the best use of the natural cycle for frozen-thawed embryo transfer? Ariel Weissman, MD IVF Unit, Dep. Ob/Gyn Wolfson Medical Center, Holon Sackler Faculty of Medicine, Tel Aviv University
More informationFertility 101. About SCRC. A Primary Care Approach to Diagnosing and Treating Infertility. Definition of Infertility. Dr.
Dr. Shahin Ghadir A Primary Care Approach to Diagnosing and Treating Infertility St. Charles Bend Grand Rounds November 30, 2018 I have no conflicts of interest to disclose. + About SCRC State-of-the-art
More informationEuropean IVF Monitoring (EIM) Year: 2013
European IVF Monitoring (EIM) Year: 2013 Name of the country Poland Name and full address of the contact person. Anna Janicka, PhD Polish Society of Reproductive Medicine and Embryology Fertility and Sterility
More informationUniversal Embryo Cryopreservation: Frozen versus Fresh Transfer. Zaher Merhi, M.D.
Universal Embryo Cryopreservation: Frozen versus Fresh Transfer Zaher Merhi, M.D. Disclosure: None Fewer complications with IVF 1.5% children in US are born through ART 1.1 million children since 2006
More informationWHAT IS A PATIENT CARE ADVOCATE?
WHAT IS A PATIENT CARE ADVOCATE? Fertility treatments can be overwhelming. As a member, you have unlimited access to a dedicated Patient Care Advocate (PCA), who acts as your expert resource for discussing
More informationNumber of oocytes and live births in IVF
Number of oocytes and live births in IVF Dr Sesh K Sunkara MD, MRCOG Royal Marsden Hospital, London Kings Healthcare Partners (Guy s & St Thomas NHS Foundation Trust), London, UK Background IVF results
More informationBiomarkers for Prediction of Pregnancy Outcome in Fertility Patients. Scott Nelson Muirhead Chair in Obstetrics & Gynaecology
Biomarkers for Prediction of Pregnancy Outcome in Fertility Patients Scott Nelson Muirhead Chair in Obstetrics & Gynaecology Why do we need to know ovarian response? Anna Sarah Just do IVF and see response
More informationAgonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M
Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M Record Status This is a critical abstract of an economic
More informationFIVNAT-CH Schweizerische Gesellschaft für Reproduktionsmedizin Société Suisse de Médecine de la Reproduction
SGRM / SSMR Schweizerische Gesellschaft für Reproduktionsmedizin FIVNAT-CH Schweizerische Gesellschaft für Reproduktionsmedizin Annual report 2013 Cycles 2012 Version 15.06.2014 Date of analysis 02.12.2013
More informationDr Guy Gudex. Gynaecologist and Fertility Specialist Repromed. 9:05-9:30 Advances in Assisted Reproduction What s New?
Dr Guy Gudex Gynaecologist and Fertility Specialist Repromed 9:05-9:30 Advances in Assisted Reproduction What s New? Rotorua GP CME June 2016 Advances in Assisted Reproduction-What s new? Dr Guy Gudex
More informationEuropean IVF Monitoring (EIM) Year: 2012
European IVF Monitoring (EIM) Year: 2012 Name of the country Poland Name and full address of the contact person. Professor Rafal Kurzawa, MD PhD Wojska Polskiego 103 Street 70-483 Szczecin Poland Telephone
More informationPresident : Indian Society for Assisted Reproduction (ISAR) Past President FOGSI. Past Chairman ICOG. Founder Trustee Women s Empowerment Foundation
Founder President: The PCOS Society, India Honorary Fellow of the Royal College of Obst.& Gyn. Prof.Duru Shah President : Indian Society for Assisted Reproduction (ISAR) Past President FOGSI. Past Chairman
More informationMyths About Success Rates Do they truly reflect quality of care
Myths About Success Rates Do they truly reflect quality of care Barry Behr PhD., HCLD Professor and IVF Laboratory Director Division of Reproductive Endocrinology and Infertility Dept OB/GYN Stanford University
More informationPGS Embryo Screening
PGS Embryo Screening Contents What are chromosomes? 3 Why should I consider chromosome testing of my embryos? 3 Embryo testing using preimplantation genetic screening (PGS) 4 How does PGS and the chromosome
More informationA mild strategy in IVF results in favourable outcomes in terms of term live birth, cost and patient discomfort
Chapter 6 A mild strategy in IVF results in favourable outcomes in terms of term live birth, cost and patient discomfort Heijnen E.M., Eijkemans M.J., De Klerk C., Polinder S., Beckers N.G., Klinkert E.R.,
More informationIVF Protocols: Hyper & Hypo-Responders, Implantation
IVF Protocols: Hyper & Hypo-Responders, Implantation Midwest Reproductive Symposium June 4-5, 4 2010 Subset : Hyper-Responders Mark R. Bush, MD, FACOG, FACS OBJECTIVE: Important goals for the PCOS patient
More informationOptimising the IVF protocol and the use of experimental and adjunctive therapies Special Interest Group Reproductive Endocrinology
28th Annual Meeting of the European Society of Human Reproduction & Embryology For more information, please visit www.eshre.eu Optimising the IVF protocol and the use of experimental and adjunctive therapies
More informationIVF AND PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) WHAT THE COMMUNITY PHYSICIAN NEEDS TO KNOW
IVF AND PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) WHAT THE COMMUNITY PHYSICIAN NEEDS TO KNOW Jon Havelock, MD, FRCSC, FACOG Co-Director - PCRM Disclosure No conflict of interest in relation
More informationTrends in Egg Donation. Vitaly A. Kushnir MD Center for Human Reproduction
Trends in Egg Donation Vitaly A. Kushnir MD Center for Human Reproduction Disclosures No relevant financial relationships to disclose CHR views the commercial trade in human oocytes with considerable ethical
More informationFactors influencing serum progesterone level on triggering day in stimulated in vitro fertilization cycles
ORIGINAL ARTICLE pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 2015;42(2):67-71 Factors influencing serum progesterone level on triggering day in stimulated in vitro fertilization cycles Ju Hee Park
More informationDo aromatase inhibitors have a place in IVF?
Do aromatase inhibitors have a place in IVF? Roy Homburg Maccabi Medical Services and Barzilai Medical Centre, Ashkelon, Israel Antalya, September, 2009 Human Follicle Growth Primordial follicle 1 layer
More informationBumiputera Sarawak Bumiputera Sabah. Others Foreigner. Had previous natural pregnancy Previous IVF pregnancies. IVF live births.
a. Date of notification: b. Name of reporting site: c.name of doctor in charge: AI : FEMALE PATIENT DETAILS & DEMOGRAPHICS (Instruction: if Mykad is not available, please complete Old IC or other ID document
More informationApproved January Waltham Forest CCG Fertility policy
Approved January 2015 Waltham Forest CCG Fertility policy Contents 1 Introduction 1 2 Individual Funding Requests 1 2.1 Eligibility criteria 1 2.2 Number of cycles funded 2 2.3 Treatment Pathway 3 Page
More informationlbt lab tests t Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour
lbt lab tests t and Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour Research Instituteof Avicenna 4/23/2012 Why good prediction of poor response good prediction i of OHSS application appropriate
More informationPrognosticating ovarian reserve by the new ovarian response prediction index
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Tak A et al. Int J Reprod Contracept Obstet Gynecol. 2018 Mar;7(3):1196-1200 www.ijrcog.org DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20180917
More informationINSIDE IVF: HOW SCIENCE CARES FOR PATIENTS DR DEIRDRE ZANDER-FOX MONASH IVF GROUP HDA GRAND ROUND OCTOBER 31 ST 2018
INSIDE IVF: HOW SCIENCE CARES FOR PATIENTS DR DEIRDRE ZANDER-FOX MONASH IVF GROUP HDA GRAND ROUND OCTOBER 31 ST 2018 IVF-THE ULTIMATE GOAL FERTILISATION EMBRYO CLEAVAGE AND DEVELOPMENT POSITIVE HCG POSITIVE
More informationFertility Preservation By Dr Mary Birdsall Chair, Fertility Associates
Fertility Preservation By Dr Mary Birdsall Chair, Fertility Associates What can you put in the Freezer and why would you? Sperm Embryos Eggs Ovarian Tissue Freezing Sperm 60 years ago first human pregnancy
More informationBrighton & Hove CCG PLS CONFERENCE Dr Carole Gilling-Smith Medical Director
Brighton & Hove CCG PLS CONFERENCE 2016 Dr Carole Gilling-Smith Medical Director FERTILITY CHALLENGES IN THE NHS A TERTIARY CARE PERSPECTIVE LEARNING OBJECTIVES Understand the pathways through assisted
More informationIndications for chromosome screening Dagan Wells, PhD, FRCPath dagan.wells@obs-gyn.ox.ac.ukgyn.ox.ac.uk Chromosome imbalance (aneuploidy) Uncontroversial data The incidence of aneuploidy Aneuploidy is
More informationClinical Study The Prognosis of IVF in Poor Responders Depending on the Bologna Criteria: A Large Sample Retrospective Study from China
BioMed Research International Volume 2015, Article ID 296173, 5 pages http://dx.doi.org/10.1155/2015/296173 Clinical Study The Prognosis of IVF in Poor Responders Depending on the Bologna Criteria: A Large
More informationPremature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles
Arch Gynecol Obstet (2010) 281:747 752 DOI 10.1007/s00404-009-1248-0 REPRODUCTIVE MEDICINE Premature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles Esra
More informationSerum progesterone levels on the day of hcg trigger and ICSI outcome: a retrospective observational cohort study
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Amin KV et al. Int J Reprod Contracept Obstet Gynecol. 2018 Aug;7(8):3194-3198 www.ijrcog.org DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20183316
More informationFertility What do GP s need to know? Richard Fisher Fertility Associates
Fertility 2010 What do GP s need to know? Richard Fisher Fertility Associates New Zealand Source: Max Planck Institute Average age of mother at first birth in New Zealand 35 30 25 20 15 10 5 0 Median Mean
More informationNew York Science Journal 2014;7(4)
The Minimal Stimulation Protocol for ICSI: An Alternative Protocol for Ovarian Stimulation Adel Elsayed Ibrahim, MD Assisted Reproductive Unit Azhar University Adel.sayed29@gmail.com Abstract: Background:
More informationPersonalizing ovarian stimulation for IVF
Personalizing ovarian stimulation for IVF Biljana Popovic-Todorovic MD,PhD Centre for Reproductive Medicine UZ Brussel QuickTime and are needed to see this picture. Controlled ovarian stimulation for IVF/ICSI
More informationPolicy updated: November 2018 (approved by Haringey and Islington s Executive Management Team on 5 December 2018)
Islington CCG Fertility Policy First approved: 29 January 2015 Policy updated: November 2018 (approved by Haringey and Islington s Executive Management Team on 5 December 2018) Introduction Islington CCG
More informationAssisted Reproduction. By Dr. Afraa Mahjoob Al-Naddawi
Assisted Reproduction By Dr. Afraa Mahjoob Al-Naddawi Learning Objectives: By the end of this lecture, you will be able to: 1) Define assisted reproductive techniques (ART). 2) List indications for various
More informationPrediction modeling for live birth in in vitro fertilization. Kristen E. Gray. A dissertation. submitted in partial fulfillment of the
Prediction modeling for live birth in in vitro fertilization Kristen E. Gray A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Washington
More information